Previous Study: TRIO029
Next Study: TRIO030
Studies & Results
TRIO-US B-07
Phase II neoadjuvant Trastuzumab or Lapatinib or trastuzumab + lapatinib followed by docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ Breast cancer.
Presentations
San Antonio Breast Cancer Symposium, 2013
Hurvitz SA, Miller JM, Dichmann R, et al
Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07).
Publications
Garon EB, Siegfried JM, Dubinett SM, et al: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
AACR 104th Annual Meeting, 2013
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
San Antonio Breast Cancer Symposium, 2013
Hurvitz SA, Miller JM, Dichmann R, et al
Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07).
Publications
Garon EB, Siegfried JM, Dubinett SM, et al: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). AACR 104th Annual Meeting, 2013
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org